Delving into the Latest Updates on HNC364 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Target-

Action-

Mechanism-

Therapeutic Areas

Nervous System DiseasesEndocrinology and Metabolic Disease

Active Indication

Parkinson Disease

Inactive Indication-

Originator Organization

Guangzhou Koncen Bioscience Co., Ltd.

Active Organization

Guangzhou Koncen Bioscience Co., Ltd.

Inactive Organization-

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

Login to view timeline

HNC364 is a new pro-drug of rasagiline as a long-acting injection for deep IM deltoid injection, for the treatment of Parkinson"s disease (PD). As a pro-drug of rasagiline, HNC364 will readily and completely convert to rasagiline after the IM administration.
This is a non-randomized, open-label, Phase 1 study to evaluate the relative bioavailability of HNC364 injectable suspension relative to AZILECT® (rasagiline tablets), to assess the safety and tolerability of multiple IM dose HNC364 injectable suspension dose administration in healthy adult subjects.

Start Date01 May 2025

Sponsor / Collaborator

Guangzhou Koncen Bioscience Co., Ltd.

NCT05523570

/ CompletedPhase 1

Phase 1, Non-randomized, Single Ascending Doses (SAD) Study Following Single Injection in Healthy Subjects to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HNC364 Injectable Suspension

This is a non-randomized, dose-escalation first-in-human study to evaluate the safety, tolerability, PK, and PD of HNC364 following intramuscular administration of single ascending doses.

Start Date22 Aug 2022

Sponsor / Collaborator-

100 Clinical Results associated with HNC364

Login to view more data

100 Translational Medicine associated with HNC364

Login to view more data

100 Patents (Medical) associated with HNC364

Login to view more data

100 Deals associated with HNC364

Login to view more data